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The objective of the present study is to evaluate the effect of the extract of a well-known hepatospeciﬁc
polyherbal formulation, Liv.52, in an experimental model of high-fat diet (HFD)-induced nonalcoholic
steatohepatitis (NASH) in rats. Feeding a HFD for 15 weeks resulted in signiﬁcant impairment of the lipid
proﬁle, elevation of hepatic enzyme markers, and insulin resistance in rats. The histological examination
of the liver furthermore indicated ﬁbrotic changes and fat deposition in hepatic tissues. The treatment
with Liv.52 extract [125 mg/kg body weight per os (b.wt. p.o.)], which was administered from week 9
onward, reversed the HFD-induced changes to a statistically signiﬁcant extent, compared to the un-
treated positive control animals. The effect observed with Liv.52 extract was comparable to that of
pioglitazone (4 mg/kg b.wt.), a standard drug that is useful in the management of NASH. The treatment
with Liv.52 extract signiﬁcantly reduced steatosis, collagen deposition, and necrosis in hepatic tissues,
which indicates its antiﬁbrotic and antinecrotic properties. The results obtained in the present set of
experiments indicate that Liv.52 extract effectively reverses metabolic and histological changes associ-
ated with HFD-induced NASH.
Copyright © 2014, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
The liver, which is the key organ of metabolism and excretion, is
constantly endowed with the task of detoxifying xenobiotics,
environmental pollutants, and chemotherapeutic agents. Disorders
associated with this organ are numerous and varied. Nonalcoholic
fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
are the most common liver diseases in the world. The mechanism
involved in the pathogenesis of NAFLD/NASH has not been thor-
oughly investigated. Some studies show that insulin resistance has
a key role in their pathogenesis. The exact mechanisms that
mediate the transition from steatosis to NASH remain unknown,
although oxidative stress and cytokine-mediated injuries may havegy, R&D Center, The Himalaya
, India.
. Raﬁq).
for Food and Biomolecules,
molecules, National Taiwan Univea key role in NASH pathogenesis.1,2 Under oxidative stress condi-
tions, reactive oxygen species (ROS) lead to membrane lipid per-
oxidation, inﬂammatory responses, stimulation of stellate cells, and
ﬁnally ﬁbrosis.3
Modern medicine has not yet found a promising curative agent.
Hence, the current use of peroxisome proliferator-activated re-
ceptor gamma (PPAR-g), corticosteroids, and immunosuppressive
agents only produce symptomatic relief. Furthermore, their usage
is associated with the risks of relapse and adverse effects.4e6
The indigenous system of medicine in India has a long tradition
of treating liver disorders with plant drugs. Liv.52 is one such
polyherbal proprietary formulations. It is approved by the Gov-
ernment of India's Drug Regulatory Authority, the department of
Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homoeopathy
(AYUSH) of the Ministry of Health and Family Welfare (New Delhi,
India). The usefulness of Liv.52 in liver disorders of various etiol-
ogies is conﬁrmed by a substantial number of clinical trials con-
ducted across the globe. It is also beneﬁcial in treating viral
hepatitis, drug-induced hepatic damage, and alcoholic liverrsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
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Liv.52 extract in an experimental model of high-fat diet (HFD)-
induced nonalcoholic steatohepatitis (NASH) in rats. In the present
study, pioglitazone, a standard reference drug that further validates
the experimental model/procedure, was used for comparative
study. The HFD model is a very appropriate model to induce NASH,
obesity, and insulin resistance. “Overnutrition” with carbohydrates
or fats or bothmay lead to obesity-related NAFLD. Insulin resistance
and obese diabetes do not solely initiate steatohepatitis, but they do
contribute to the progression of the entire spectrum of pathology of
steatohepatitis, at least partly, via the upregulation of genes
involved in lipogenesis, inﬂammation, and ﬁbrogenesis. Agonists of
PPAR-g reportedly prevent the progression of NASH in a dietary
model of NASH associated with obese diabetes.112. Composition and preparation of Liv.52 extract
The Liv.52 extract constitutes a mixture of roots of Capparis
spinosa (續隨子根 xù suí zǐ), seeds of Cichorium intybus (菊苣 jú jù),
whole plant of Solanum nigrum (龍葵 long kuí), Terminalia arjuna
(bark), seed of Cassia occidentalis (望江南 wang jiang nan), Achillea
millefolium (洋蓍草 yang shı cǎo; aerial plant), and Tamarix gallica
(whole plant). These crude herbal materials were subjected to
pulverization to obtain their coarse powders, and then blended.
They were then soaked in pure water and boiled in a steam-
jacketed stainless steel reactor until the extraction was complete.
The liquid extract thus obtained was ﬁltered through a muslin cloth
and concentrated in the reactors to attain 30% total solids. The soft
extract was then subjected to spray drying to obtain the dry extract
powder. It was tested for its quality and consistency at each
manufacturing step per the accepted principles of good
manufacturing practice (GMP) and good laboratory practice (GLP).
Its botanical identiﬁcation, quality parameters, and Ayurvedic
criteria complied with the international guidelines and pharma-
copoeial standards.12,133. High-performance liquid chromatography and liquid
chromatographyemass spectrometry/mass spectroscopy
ﬁngerprinting of Liv.52 extract
3.1. Sample preparation and liquid chromatographic conditions
The concentration of the Liv.52 extract (DD-100) was 10 mg/mL
in methanol. Liquid chromatography was performed by the Shi-
madzu LC-20AD series pump (Shimadzu Corporation, Kyoto, Japan)
and DUG-20A3 series Shimadzu degasser (Shimadzu Corporation,
Kyoto, Japan). Chromatographic separation was performed on the
Luna C18 column (250 mm  4.6 mm, 5 mm; Phenomenex, Tor-
rance, CA, USA). For the separation, the mobile phase gradient
consisted of water (J.T. Baker brand; Avantor Performance Mate-
rials, Inc., Center Valley, PA, USA) with 10mM ammonium acetate
and 0.1% formic acid in pump A and acetonitrile (J.T. Baker brand;
Avantor PerformanceMaterials, Inc.) in pump B. The linear gradient
programwas set as follows: 0e27 minutes of 20% of acetonitrile to
80% acetonitrile (linear); 27e30 minutes of 80% acetonitrile to 20%
acetonitrile (linear); followed by 30 minutes of 20% acetonitrile
(isocratic) equilibration period for 2 minutes, delivered at a ﬂow
rate of 0.6 mL/min and a run time of approximately 32 minutes.
Peak elution was monitored at 245 nm and 360 nm through the
Shimadzu SPD-20A UV/VIS detector (Shimadzu Corporation). The
injection volume of 20 mL was injected through the SIL-HTC Shi-
madzu Autosampler (Shimadzu Corporation). The ambient tem-
perature was achieved through a CTO-10 AS VP column oven
(Shimadzu Corporation) at 25 C.3.2. Mass spectrometric conditions
The API 2000 mass spectrometer (Applied Biosystems/MDS
SCIEX, Ontario, Canada) was coupled with an electron spray ioni-
zation source and a chromatographic system. Batch acquisition and
data processing were controlled by Analyst 1.5 version software.
Optimization of the mass spectroscopy (MS) parameters was
performed with 2 mg/mL of test solutions that were prepared
separately and diluted in methanol (J.T. Baker brand; Avantor Per-
formance Materials, Inc.). The intensity response was checked in
the positive ionization mode and negative ionization mode. The
intense response was good in the positive mode. Interface condi-
tions such as the declustering potential (40 V), ion spray voltage
(3500 V), nebulizing gas [GS1 (55 psi) and GS2 (65 psi)], curtain gas
(25 psi), focusing potential (400 V), entrance potential (10 V), and
source temperature (420 C) were optimized by multiple runs
through liquid chromatography. Acquisition was performed by
setting the mass of the analytes with the appropriate scan range.
(Fig. 1).
4. Materials and methods
4.1. Drugs and chemicals
Liv.52 extract was procured from the Phytochemistry Depart-
ment of The Himalaya Drug Company (Bangalore, India) and pio-
glitazone was procured from Sun Pharmaceuticals Industries Ltd.
(Mumbai, India). Cholic acid and cholesterol were procured from
HiMedia Laboratories Ltd. (Mumbai, India). All other chemicals
used in the study were of reagent/analytical grade from reputed
suppliers. Biochemical parameters such as glucose, cholesterol,
triglycerides (TGs), serum glutamic oxaloacetic transaminase
(SGOT), serum glutamate pyruvate transaminase (SGPT), and
alkaline phosphatase (ALP) were estimated in a biochemistry
autoanalyzer (EM-360; Erba Diagnostics Mannheim GmbH, Man-
nheim, Germany) using ready-made assay kits (Erba kits; Erba Di-
agnostics Mannheim GmbH). Insulin was estimated using a
radioimmunoassay kit (RIAK-1) supplied by Bhabha Atomic
Research Centre/Board of Radiation and Isotope Technology (BARC/
BRIT; Mumbai, India).
4.2. Experimental animals
Inbred male Wistar rats (260e280 g) were housed under stan-
dard conditions of temperature (22 ± 3 C) at a relative humidity of
55 ± 5% and 12-hour light/dark cycle prior to and during the study.
The normal group animals were fed a standard pellet diet (Provimi
Animal Nutrition India Pvt. Ltd., Bangalore, Karnataka, India), and
water ad libitum. The experimental protocols were approved by the
Institutional Animal Ethics Committee (IAEC) of The Himalaya Drug
Company (Bangalore, India). The animals received humane care as
prescribed by the guidelines of the Committee for the Purpose of
Control and Supervision on Experiments on Animals (CPCSEA),
Ministry of Environment and Forests, Government of India (New
Delhi, India).
4.3. Composition of HFD
The HFD consisted of 87.5% normal laboratory rodent feed, 10%
animal fat, 0.5% cholic acid, and 2% cholesterol.14
4.4. HFD-induced nonalcoholic steatohepatitis
Male Wistar rats (n ¼ 36) that weighed 260e280 g were
randomly divided into four groups consisting of nine animals each.
Fig. 1. The chromatograms of Liv.52 extract by (A) high-performance liquid chromatography (LC) and (B) mass spectroscopy (MS).
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HFD for 60 days. After 60 days, blood was collected from the retro-
orbital plexus under mild ether anesthesia to determine the lipid
proﬁle and to ensure that all rats in the HFD-fed groups were
hyperlipidemic. After conﬁrmation, the rats were segregated. All
rats received an equal amount of water (10 mL/kg b.wt.) as a
vehicle. Group I (i.e., animals fed a normal diet) served as normal
control, Group II (i.e., animals fed a HFD) served as the positive
control, and Group III rats received Liv.52 extract (125 mg/kg b.wt.)
along with HFD. The dose was selected based on dose range ﬁnding
studies performed in the laboratory to evaluate its hep-
atoprotective activity in rats; the dosing volumewas determined by
the weekly mean group body weight of the animals. Group IV rats
ingested a HFD and received pioglitazone (4 mg/kg b.wt.).
Each group received its respective assigned treatment orally
once daily for 42 days. Daily clinical observations and the weekly
body weights of the animals were recorded for all groups. At the
end of the treatment period, the animals underwent 12-hour
fasting. Their blood was collected from the retro-orbital plexus
under mild ether anesthesia to estimate biochemical parameters
such as glucose, insulin, cholesterol, TG, SGPT, SGOT, and ALP. After
collecting their blood, the rats were euthanized by deep ether
anesthesia. A small portion of their liver was ﬁxed in formalin,
subjected to routine histological procedures, and stained with he-
matoxylin and eosin (H&E) and Masson trichrome.15e17
The serum insulin was estimated by standard radioimmuno-
assay technique using a kit (RIAK-1) supplied by BARIC/BRIT
(Mumbai, India). The degree of insulin resistance was estimated by
using the homeostasis model assessment (HOMA) as the index of
insulin resistance.18 The formula for the HOMA index is:
HOMA index¼ InsulinðmU per literÞglucoseðmmol per literÞ
22:5
4.5. Statistical analysis
All values are expressed as the mean ± standard error of the
mean (SEM). The results were statistically analyzed by one-way
analysis of variance (ANOVA), followed by Dunnett's post test, us-
ing Prism GraphPad 4.03 software, Windows version (GraphPad
Software Inc., San Diego, CA, USA). A p value <0.05 was considered
statistically signiﬁcant.
5. Results and discussion
The present study evaluated the effect of Liv.52 extract in an
experimental model of HFD-induced NASH in rats. Feeding ani-
mals a HFD signiﬁcantly impaired the lipid proﬁle and elevatedTable 1
The serum biochemical parameters of the rats.
SGOT (IU/L) SGPT (IU/L) ALP (IU/L) Cho
(m
Normal control 152.3 ± 5.7 69.8 ± 1.7 164.3 ± 10.3 97.
Positive control (untreated) 199.6 ± 6.7b 88.5 ± 5.1a 272.4 ± 25.4b 1
Liv.52 extract (125 mg/kg p.o.) 163.6 ± 7.5c 71.7 ± 6.2c 190.5 ± 12.6d 113
Pioglitazone (4 mg/kg p.o.) 163.0 ± 18.0c 69.4 ± 2.6d 201.2 ± 13.2c 116
All values are expressed as the mean ± the standard error of the mean (SEM).
ALP ¼ alkaline phosphatase; HOMA ¼ homeostasis model assessment; p.o. ¼ per os; SG
transaminase; TG ¼ triglyceride.
a Indicates signiﬁcance at p < 0.05, compared to the normal control.
b Indicates signiﬁcance at p < 0.01, compared to the normal control.
c Indicates signiﬁcance at p < 0.05, compared to the positive control.
d Indicates signiﬁcance at p < 0.01, compared to the positive control.the level of serum insulin, glucose, and liver function marker en-
zymes SGPT, SGOT, and ALP. The changes were statistically sig-
niﬁcant, compared to the normal controls (i.e., animals fed a
normal diet). Treatment with the Liv.52 extract was initiated at the
end of 9th week of HFD supplementation. Group IV animals were
treated with pioglitazone, which was used as the reference
standard.
Forty-two days of treatment orally with Liv.52 extract (125 mg/
kg) reversed the elevated serum markers SGOT, SGPT, ALP, and
reversed the cholesterol and TG levels to a statistically signiﬁcant
extent, compared to the untreated HFD control animals. The oral
administration of pioglitazone (4 mg/kg) also decreased the
aforementioned serum parameters to a statistically signiﬁcant
level, compared to the positive untreated control (Table 1).
Insulin resistance that developed because of the intake of a HFD
was also decreased in animals treated with Liv.52 extract or pio-
glitazone. This difference was statistically signiﬁcant, compared to
the positive untreated HFD animals. Liv.52 extract and pioglitazone
both decreased the fasting serum glucose, the insulin level, and the
HOMA index, which are measures of insulin resistance (Table 1).
The histopathological examination and scoring of the liver
sections (stained by H&E and Masson trichome) also revealed the
beneﬁcial effect of Liv.52 extract and pioglitazone in reversing
many of the pathological changes associated with a HFD in rats.
Most notably, the drugs signiﬁcantly reduced collagen deposition,
necrosis, and steatosis in hepatic tissues, which are hallmarks of
NASH (Table 2 and Figs. 2 and 3). Nonalcoholic steatohepatitis re-
fers to a spectrum of hepatic pathology that resembles alcoholic
liver disease, but appears in individuals who have low or negligible
alcohol consumption. Nonalcoholic fatty liver disease ranges from a
fatty liver alone to NASH. Increasing evidence suggests that NASH is
associated with progressive ﬁbrosis, cirrhosis, and eventually he-
patocellular cancer.19 It has been suggested that the term “nonal-
coholic fatty liver disease” should be used only for the more severe
forms of NAFLD that correspond to types 3 and 4with alcoholic-like
histological ﬁndings. The medical conditions most frequently
associated with NAFLD and NASH are obesity, diabetes mellitus,
and dyslipidemia.20
The HFD model is useful in reproducing the human condition
because it contains predominantly saturated fat intake, which is
positively correlated with the insulin sensitivity index, and alanine
aminotransferase levels in patients with NASH. Peripheral insulin
resistance can induce hepatic steatosis, which then causes insulin
resistance in the liver and is characterized by a reduced insulin-
suppressing effect in hepatic glucose production; this aggravates
peripheral insulin resistance and contributes to hepatic
lipogenesis.21
Insulin resistance is a complex metabolic abnormality that af-
fects the ability of peripheral tissues to respond to insulin. It is a
prominent feature of metabolic syndrome and type 2 diabetes, andlesterol
g/dL)
TG (mg/dL) Fasting glucose
(mg/dL)
Insulin (mU/mL) HOMA index
88 ± 3.7 117.4 ± 14.3 64.33 ± 3.3 27.93 ± 3.5 3.857 ± 0.44
46 ± 10a 174.3 ± 12.4a 78.5 ± 5.2a 52.71 ± 3.6b 7.678 ± 0.44a
.1 ± 8d 106.9 ± 12d 48.43 ± 2.8d 35.33 ± 2.5c 4.686 ± 0.43d
.8 ± 6.3c 144.5 ± 21.6c 48 ± 3.1d 34.00 ± 6.23c 4.671 ± 0.43d
OT ¼ serum glutamic oxaloacetic transaminase; SGPT ¼ serum glutamate pyruvate
Table 2
Histopathological ﬁndings of the rat liver samples among the four groups.
Normal control Positive control
(untreated)
Liv.52 extract
(125 mg/kg b.wt.)
Pioglitazone
(4 mg/kg b.wt.)
H&E stain
Inﬂammatory reaction 0.778 ± 0.32 2.000 ± 0.29a 1.444 ± 0.24 1.333 ± 0.33
Biliary hyperplasia 0.556 ± 0.29 2.444 ± 0.34b 0.222 ± 0.22d 0.667 ± 0.33d
Fat vacuolating accumulation in parenchyma 0.000 ± 0.00 3.333 ± 0.21b 2.857 ± 0.50 1.714 ± 0.47c
Necrosis in parenchyma 0.000 ± 0.00 1.571 ± 0.28b 0.428 ± 0.29d 0.222 ± 0.15d
Masson’s trichrome stain
Collagen deposition 0.667 ± 0.29 3.500 ± 0.18b 1.714 ± 0.29d 1.875 ± 0.44d
Fat vacuolating accumulation 0.000 ± 0.00 3.333 ± 0.21b 2.857 ± 0.50 1.714 ± 0.47c
H&E Stain (score):
Inﬂammatory reaction (score of 1e3)
Biliary hyperplasia (score of 1e3)
Fat vacuolating accumulation (score of 1e4)
Necrosis in parenchyma [score-focal (1) and multi-focal (2)]
Masson's trichrome Stain (score):
Collagen deposition (score of 1e4)
Fat vacuolating accumulation in the parenchyma (score of 1e4)
All values are expressed as the mean ± the standard error of the mean (SEM).
b.wt. ¼ body weight; H&E ¼ hematoxylin and eosin.
a Indicates signiﬁcance at p < 0.05, compared to the normal control.
b Indicates signiﬁcance at p < 0.01, compared to the normal control.
c Indicates signiﬁcance at p < 0.05, compared to the positive control.
d Indicates signiﬁcance at p < 0.01, compared to the positive control.
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close interplay between increased tumor necrosis factor (TNF)-a
expression, insulin resistance, and lipolysis in adipose tissue that
results in the increased delivery of free fatty acids, TNF-a, and
cortisol to the liver, which initially lead to the development of
steatosis. In patients with NAFLD, increased fat accumulation
eventually results in hepatic insulin resistance. The insulin resis-
tance increases fat oxidation, which in association with TNF-a,Fig. 2. Photomicrographs of the liver sections show (A) normal structure and architectu
macrovesicular steatosis in the positive control animals fed a high-fat diet; (C) Grade 2 stea
kg body weight; and (D) Grade 2 steatosis in animals fed a high-fat diet and treated with
100).generates oxidative stress and mitochondrial uncoupling. The
expression of TNF-a and mitochondrial dysfunction leads to he-
patocyte death, inﬂammation, and ultimately ﬁbrosis.22,23
In the present study, the effect of Liv.52 extract was compared
with pioglitazone, whichwas used as the reference standard in a rat
model of NASH. Previous reports indicate the usefulness of piogli-
tazone in an experimental model of NASH in rats.24 Pioglitazone is
also a reasonable option for treating NASH, particularly in patientsre in the normal control animals fed a normal diet; (B) severe microvesicular and
tosis in animals fed a high-fat diet and treated with Liv.52 extract at a dose of 125 mg/
piglitazone at a dose of 4 mg/kg body weight (hematoxylin and eosin; magniﬁcation,
Fig. 3. Photomicrographs of liver sections show(A) no collagen deposition in the normal control animals fed a normal diet; (B) severe perivascular edema and collagen deposition in
the positive control animals fed a high-fat diet; (C) Grade 2 collagen deposition around the periportal zone and perivascular necrosis and edema in animals treated with Liv.52
extract (12 mg/kg body weight); and (D) mild steatosis and collagen deposition in animals treated with picoglitazone (4 mg/kg body weight) (Masson's trichome; magniﬁcation,
100).
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glitazone therapy was associated with reduced hepatocellular
injury and ﬁbrosis in patients with NASH. However, the cardio-
vascular beneﬁterisk ratio of this drug must at least be
considered.25
Oxidative stress may contribute to the development of several
age-related and chronic diseases such as cancer, diabetes, neuro-
degenerative diseases, and cardiovascular diseases.26e28 In partic-
ular, ROS and reactive nitrogen species have a crucial role in disease
induction and in the progression of liver diseases such as hepato-
cellular carcinoma, viral and alcoholic hepatitis, and nonalcoholic
steatosis.29,30 In our previous studies, Liv.52 extract exhibited a
potent beneﬁcial effect in regulating oxidative stress induced by
various liver toxicants. It abrogates copper (II)-induced cytotoxicity
in HepG2 cells by inhibiting lipid peroxidation, increasing the
glutathione content, and increasing endogenous antioxidant
enzyme activities.31 By preventing intracellular glutathione
depletion and lipid peroxidation, it also reportedly inhibits hepatic
cell death evoked by tertiary-butyl hydroperoxide.32
There are other reports that indicate the usefulness of plant-
based antioxidants in the management of NASH. Genistein is a
strong antioxidant agent that is capable of decreasing the plasma
TNF-a level and attenuating the incidence of NASH33. A Chinese
polyherbal blend comprising Panax pseudoginseng (三七 san qı),
Eucommia ulmoides (杜仲 dù zhong), Polygonati rhizoma (黃精
huang jıng), and licorice root (甘草根 gan cǎo gen) reportedly
markedly reduces macrosteatosis while signiﬁcantly improving
histological markers of inﬂammation in HFD-fed experimental
animals. These effects have also been associated with a marked
reduction in serum aminotransferases and hepatic lipoperoxide
and glutathione content, which implies that the herbal complex has
noticeable antioxidant activity.34Nonalcoholic steatohepatitis is histologically characterized by
diffuse fatty inﬁltration, lobular inﬂammation, ballooning degen-
eration, and ﬁbrosis in the liver.35,36 In the present study, many liver
histopathological features of animals fed a HFD were similar to the
ﬁndings of other published reports, and the treatment by Liv.52
extract or pioglitazone signiﬁcantly reversed these histopatholog-
ical anomalies (Figs. 2 and 3). The Liv.52 extract treatment signiﬁ-
cantly reduced steatosis, collagen deposition, and necrosis of
hepatic tissues, which indicate its antiﬁbrotic and antinecrotic
properties. Increased mean body weight occurred in the animals
treated a HFD, compared to the normal control group; however,
this difference was not statistically signiﬁcant. The treated groups
showed amarginal decrease in mean body weight in comparison to
the positive untreated controls; however, this ﬁnding was similarly
insigniﬁcant (Fig. 4).
The results of the present study showed that the treatment with
the Liv.52 extract was comparable to pioglitazone at the selected
dose, by the method employed, and by the mode of administration.
The mechanism behind the beneﬁcial action of Liv.52 extract in the
present experimental model of NASH could be because of its potent
antioxidant and other hepatospeciﬁc actions, as reported
previously.
6. Conclusion
From the biochemical and histopathological data obtained in the
present study, the treatment by Liv.52 extract administered orally
at a daily dose of 125 mg/kg b.wt. exhibited a beneﬁcial effect by
reversing serum biochemical parameters in rats with NASH
induced by a HFD. The Liv.52 extract treatment also signiﬁcantly
reduced steatosis, collagen deposition, and necrosis in hepatic tis-
sues, which indicate its antiﬁbrotic and antinecrotic properties. The
Fig. 4. The mean body weight change in the different groups.
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selected dose, by the method employed, and by the mode of
administration. The mechanism behind the beneﬁcial action of
Liv.52 extract in the present experimental model of NASH could be
because of its potent antioxidant and other hepatospeciﬁc actions,
as previously reported in the literature.Conﬂicts of interest
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